Want to see QTTB full AI Analyst Report?
Top Page
Q32 Bio
(NASDAQ:QTTB)
Select Model
Select Model
Rating:57Neutral
Price Target:
$8.50
▼(-47.92% Downside)
Action:Reiterated
Date:10/01/26
The score is driven primarily by improved reported profitability and a healthier current balance sheet, offset by continued cash burn and historically volatile financials. Technically, the stock is in a pronounced downtrend with weak momentum despite oversold readings. Valuation is a support due to a very low P/E, and recent clinical/program execution events are positive, but they do not fully outweigh cash-flow and trend risks.
Positive Factors
Clinical efficacy and durability
Bempikibart’s Phase 2a efficacy, durability signals, and generally well-tolerated safety profile support advancement into registration-directed studies. Positive results across severe disease and prior JAK inhibitor exposure could broaden the program’s clinical relevance if confirmed in later trials.
Negative Factors
No established product revenue
Because Q32 Bio remains focused on clinical development rather than selling approved products, it lacks an established commercial revenue base to fund operations. Financial progress therefore depends heavily on advancing candidates successfully and securing external or strategic funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy and durability
Bempikibart’s Phase 2a efficacy, durability signals, and generally well-tolerated safety profile support advancement into registration-directed studies. Positive results across severe disease and prior JAK inhibitor exposure could broaden the program’s clinical relevance if confirmed in later trials.
Read all positive factors
Q32 Bio (QTTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$259.29M
Dividend YieldN/A
Average Volume (3M)942.45K
Price to Earnings (P/E)3.1
Beta (1Y)0.21
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.79
Shares Outstanding29,769,466
10 Day Avg. Volume568,284
30 Day Avg. Volume942,450
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda4.58
Forecast
1Y Price Target
$39.43Price Target Upside141.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$285.71K
Q32 Bio Business Overview & Revenue Model
Company Description
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disord...
How the Company Makes Money
Q32 Bio is a clinical-stage biotech and, as such, it does not primarily generate revenue from selling approved products. Its funding typically comes from external financing and strategic sources rather than operating sales. Specific, company-verif...
Q32 Bio Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.74M | 53.74M | 0.00 | -6.65M | 6.65M | 0.00 |
| Gross Profit | 53.65M | 53.74M | 0.00 | -6.65M | 6.65M | 0.00 |
| EBITDA | 34.53M | 31.31M | -44.50M | -47.76M | -38.85M | -27.15M |
| Net Income | 33.79M | 29.82M | -47.73M | -53.74M | -42.81M | -37.56M |
Balance Sheet | ||||||
| Total Assets | 115.87M | 61.78M | 92.33M | 47.06M | 229.53M | 211.72M |
| Cash, Cash Equivalents and Short-Term Investments | 106.27M | 48.30M | 77.97M | 25.62M | 175.03M | 155.87M |
| Total Debt | 5.30M | 15.34M | 18.90M | 50.84M | 29.95M | 23.93M |
| Total Liabilities | 9.96M | 19.76M | 86.66M | 229.98M | 51.54M | 42.07M |
| Stockholders Equity | 105.91M | 42.01M | 5.67M | -182.92M | 177.98M | 169.65M |
Cash Flow | ||||||
| Free Cash Flow | -19.83M | -33.54M | -67.79M | -18.68M | -13.44M | -112.15M |
| Operating Cash Flow | -19.83M | -33.54M | -67.72M | -18.68M | -10.96M | -109.75M |
| Investing Cash Flow | 7.00M | 7.00M | 19.93M | -5.00K | -2.47M | -50.79M |
| Financing Cash Flow | 64.27M | -3.13M | 95.14M | 406.00K | 30.07M | 52.17M |
Q32 Bio Technical Analysis
Neutral
16.32
Price Trends
10.85
Negative
12.57
Negative
9.15
Negative
Market Momentum
-0.54
Negative
45.37
Neutral
76.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTTB, the sentiment is Neutral. The current price of 16.32 is above the 20-day moving average (MA) of 8.27, above the 50-day MA of 10.85, and above the 200-day MA of 9.15, indicating a neutral trend. The MACD of -0.54 indicates Negative momentum. The RSI at 45.37 is Neutral, neither overbought nor oversold. The STOCH value of 76.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for QTTB.
Q32 Bio Risk Analysis
Q32 Bio disclosed 84 risk factors in its most recent earnings report. Q32 Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Q32 Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $259.29M | 3.12 | 76.88% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $136.51M | -2.03 | -708.20% | ― | ― | 30.16% | |
49 Neutral | $39.34M | -1.49 | -35.78% | ― | ― | -43.60% | |
42 Neutral | $8.63M | -0.11 | -1270.11% | ― | ― | 69.34% | |
42 Neutral | $8.95M | -0.19 | 3398.40% | ― | ― | 15.37% | |
39 Underperform | $5.81M | -0.11 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
QTTB
Q32 Bio
9.06
6.38
238.06%
TPST
Tempest Therapeutics
0.54
-10.28
-95.02%
PDSB
PDS Biotechnology
1.52
0.51
50.50%
GRCE
Grace Therapeutics
2.01
-1.12
-35.78%
CALC
CalciMedica
1.66
-13.19
-88.82%
SNTI
Senti Biosciences
0.22
-1.93
-90.00%
Q32 Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Q32 Bio advances bempikibart in alopecia areata program
Positive
Sep 30, 2026
On September 30, 2026, Q32 Bio reported detailed 36-week treatment and 16-week off-drug data from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata, presented as a late-breaker at the European Academy o...
Business Operations and StrategyExecutive/Board Changes
Q32 Bio Appoints New Clinical and Development Leadership
Positive
Sep 14, 2026
On September 14, 2026, Q32 Bio announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Trevejo brings more than two decades of dermatology and late-stage ...
Business Operations and Strategy
Q32 Bio Reports Positive Phase 2a Alopecia Areata Results
Positive
Jul 13, 2026
On July 13, 2026, Q32 Bio announced topline 36‑week results from Part B of its Phase 2a SIGNAL‑AA trial of bempikibart in alopecia areata, showing robust clinical activity and a favorable safety profile with no Grade 3 or higher advers...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Q32 Bio Reports Positive Alopecia Phase 2a Data
Positive
Jul 13, 2026
On July 13, 2026, Q32 Bio reported positive 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial testing bempikibart in 33 patients with severe or very severe alopecia areata, including those previously treated with JAK inhibitors. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.